Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials

Most academic precision oncology programs have been designed to facilitate enrollment of patients in early clinical trials with matched targeted agents. Over the last decade, major changes were seen both in the targetable molecular alteration landscape and in drug development trends. In this article...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:JCO Precis Oncol
المؤلفون الرئيسيون: Dienstmann, Rodrigo, Garralda, Elena, Aguilar, Susana, Sala, Gemma, Viaplana, Cristina, Ruiz-Pace, Fiorella, González-Zorelle, Jenifer, Grazia LoGiacco, Deborah, Ogbah, Zighereda, Ramos Masdeu, Laia, Mancuso, Francesco, Fasani, Roberta, Jimenez, Jose, Martinez, Paola, Oaknin, Ana, Saura, Cristina, Oliveira, Mafalda, Balmaña, Judith, Carles, Joan, Macarulla, Teresa, Elez, Elena, Alsina, Maria, Braña, Irene, Felip, Enriqueta, Tabernero, Josep, Rodon, Jordi, Nuciforo, Paolo, Vivancos, Ana
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Clinical Oncology 2020
الموضوعات:
Special Articles
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446427/
https://ncbi.nlm.nih.gov/pubmed/32923891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.19.00398
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة